Presentation is loading. Please wait.

Presentation is loading. Please wait.

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian.

Similar presentations


Presentation on theme: "Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian."— Presentation transcript:

1 Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON)  Noortje Thielen, Bronno van der Holt, Jan J. Cornelissen, Gregor E.G. Verhoef, Titia Gussinklo, Bart J. Biemond, Simon M.G. Daenen, Wendy Deenik, Rien van Marwijk Kooy, Eefke Petersen, Willem M. Smit, Peter J.M. Valk, Gert J. Ossenkoppele, Jeroen J.W.M. Janssen  European Journal of Cancer  Volume 49, Issue 15, Pages (October 2013) DOI: /j.ejca Copyright © 2013 Elsevier Ltd Terms and Conditions

2 Fig. 1 Time from randomisation until loss of MR4.5.
European Journal of Cancer  , DOI: ( /j.ejca ) Copyright © 2013 Elsevier Ltd Terms and Conditions

3 Supplementary File 1 Successive dose levels of cytarabine and imatinib in the HOVON 51 study. European Journal of Cancer  , DOI: ( /j.ejca ) Copyright © 2013 Elsevier Ltd Terms and Conditions

4 Supplementary File 2 Flow diagram of imatinib stop study.
European Journal of Cancer  , DOI: ( /j.ejca ) Copyright © 2013 Elsevier Ltd Terms and Conditions


Download ppt "Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian."

Similar presentations


Ads by Google